EPA:ABVX - Euronext Paris - Matif - FR0012333284 - Common Stock - Currency: EUR
EPA:ABVX (3/7/2025, 7:00:00 PM)
7.35
-0.33 (-4.3%)
The current stock price of ABVX.PA is 7.35 EUR. In the past month the price increased by 28.72%. In the past year, price decreased by -43.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 62 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 62
Company Website: https://www.abivax.com/
Investor Relations: http://abivax.com/investors/
Phone: 33153830963
The current stock price of ABVX.PA is 7.35 EUR. The price decreased by -4.3% in the last trading session.
The exchange symbol of ABIVAX SA is ABVX and it is listed on the Euronext Paris - Matif exchange.
ABVX.PA stock is listed on the Euronext Paris - Matif exchange.
12 analysts have analysed ABVX.PA and the average price target is 28.46 EUR. This implies a price increase of 287.18% is expected in the next year compared to the current price of 7.35. Check the ABIVAX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABIVAX SA (ABVX.PA) has a market capitalization of 465.87M EUR. This makes ABVX.PA a Small Cap stock.
ABIVAX SA (ABVX.PA) currently has 62 employees.
ABIVAX SA (ABVX.PA) has a support level at 6.73 and a resistance level at 7.64. Check the full technical report for a detailed analysis of ABVX.PA support and resistance levels.
The Revenue of ABIVAX SA (ABVX.PA) is expected to grow by 628.34% in the next year. Check the estimates tab for more information on the ABVX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABVX.PA does not pay a dividend.
ABIVAX SA (ABVX.PA) will report earnings on 2025-03-24, after the market close.
ABIVAX SA (ABVX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.2).
ChartMill assigns a technical rating of 4 / 10 to ABVX.PA. When comparing the yearly performance of all stocks, ABVX.PA is a bad performer in the overall market: 95.49% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ABVX.PA. The financial health of ABVX.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ABVX.PA reported a non-GAAP Earnings per Share(EPS) of -3.2. The EPS decreased by -10.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.37% | ||
ROE | -140.29% | ||
Debt/Equity | 0.48 |
ChartMill assigns a Buy % Consensus number of 87% to ABVX.PA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -6.86% and a revenue growth 628.34% for ABVX.PA